The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-24. Anything still debated is marked as such rather than presented as settled.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
Storage recommendations for ipamorelin usually focus on temperature, moisture, and light. Lyophilized powder is typically held at or below minus twenty degrees Celsius in a desiccated container protected from light. Reconstituted solutions are often aliquoted and stored at minus eighty degrees Celsius to reduce repeated freeze-thaw cycles, which can promote aggregation or degradation. The optimal buffer and pH depend on the specific assay, and no single condition applies to every experimental context. Peptide stability should be assessed with time-point measurements rather than assumed from general handling rules.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with amidated C-terminus |
| Molecular weight | 711.85 g/mol | Monoisotopic mass |
| Primary receptor | GHS-R1a | Ghrelin receptor, Gq/11 coupled |
| Peptide class | Synthetic pentapeptide | Contains two non-natural residues |
| Reported selectivity | Lower cortisol and prolactin effect | Observed in animal and early human work |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Verification of identity and purity relies on analytical methods used across peptide chemistry. Reverse-phase high-performance liquid chromatography separates components by hydrophobicity and provides a purity estimate. Mass spectrometry confirms molecular mass and helps detect modifications. Together these techniques give complementary information about whether a sample matches its expected structure. Results depend on method parameters and reference standards, so reported purity values are meaningful only when the analytical conditions are stated. Consistency between laboratories requires comparable protocols and well-characterized reference materials.
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
=== Other lawsuits === On April 9, 2019, Nations Restaurant News reported that Burger King filed a lawsuit on Fritz Management LLC to remove Burger King trademarks from 37 units in South Texas after unsanitary conditions were found at a restaurant in Harlingen, Texas. In May 2019, the lawsuit was settled with the franchisee, Fritz Management (a subsidiary of Sun Holdings Inc), keeping the trademarks on all 37 units.
Fibromyalgia (FM) is a long-term condition characterised by widespread chronic pain. Other symptoms can include fatigue, trouble thinking or remembering, waking up tired (unrefreshed), pain or cramps in the lower abdomen, depression, or headache. The causes of fibromyalgia are unknown, with several pathophysiologies proposed. Fibromyalgia is estimated to affect 2 to 4% of the population. Women are affected at a higher rate than men. Rates appear similar across areas of the world and among varied cultures. Fibromyalgia was first recognised in the 1950s, and defined in 1990, with updated criteria in 2011, 2016, and 2019. The treatment of fibromyalgia is symptomatic and multidisciplinary. Aerobic and strengthening exercise is recommended. Duloxetine, milnacipran, and pregabalin can give short-term pain relief to some people with FM. Symptoms of fibromyalgia persist long-term in most patients. Fibromyalgia is associated with a significant economic and social burden, and it can cause substantial functional impairment among people with the condition. People with fibromyalgia can be subjected to significant stigma and doubt about the legitimacy of their symptoms, including in the healthcare system. FM is associated with relatively high suicide rates.
=== Nonmedical use === Dexamethasone is given to prostituted Bangladeshi children, causing weight gain aimed at making them appear older and healthier to customers and police. Dexamethasone and most glucocorticoids are banned by sporting bodies including the World Anti-Doping Agency.
Sources: en.wikipedia.org
=== In Jabal al-Druze === According to expert Fabrice Balanche, during the 18th and 19th centuries, there were significant migrations of Druze from Mount Lebanon to Jabal Hauran, which eventually became known as Jabal al-Druze ('mountain of the Druze'). The region also had sizable integrated Christian communities that had coexisted with the Druze for centuries, living in harmony with them. Historian Kais Firro asserts that in Hauran, during the 18th and 19th centuries, Christians welcomed the arrival of new Druze immigrants as allies in repelling invasions by Bedouin clans. He also observes that prior to Syrian independence, Christian villages in Hauran enjoyed protection from Druze clans, such as Al-Hamdan and Al-Atrash, shielding them from frequent attacks by Bedouins from neighboring regions. Frederick J. Bliss notes that, to avoid Turkish military service, some Druze claimed to be Protestants. A French officer stationed in Houran confirmed that if aristocratic Druze families lost a child, they would baptize the next-born child. The second son of Sultan al-Atrash was baptized in 1924. These practices reflect piety, and it's not uncommon for a Druze living in a predominantly Christian villages to contribute financially to the local church. Many Armenians who escaped Anatolia during the Armenian genocide sought refuge in Houran and Jabal al-Druze, where they received additional support from the Druze community. The Druze of Houran and Jabal al-Druze provided shelter and defense to Armenian refugees.
Herbal medicine (also called herbalism, phytomedicine or phytotherapy) is the study of pharmacognosy and the use of medicinal plants, which are a basis of traditional medicine. Scientific evidence for the effectiveness of many herbal treatments remains limited, prompting ongoing regulatory evaluation and research into their safety and efficacy. Standards for purity or dosage are generally not provided. The scope of herbal medicine sometimes includes fungal and bee products, as well as minerals, shells and certain animal parts. Paraherbalism is the pseudoscientific use of plant or animal extracts as medicine, relying on unproven beliefs about the safety and effectiveness of minimally processed natural substances. Herbal medicine has been used since at least the Paleolithic era, with written records from ancient Sumer, Egypt, Greece, China, and India documenting its development and application over millennia. Modern herbal medicine is widely used globally, especially in Asia and Africa. Traditional medicine systems involve long-standing, culturally-embedded practices using local herbs, animal products, and spiritual elements. These systems have influenced and contributed to modern pharmacology. Herbalists believe that plants, having evolved defenses against environmental stressors, produce beneficial phytochemicals, often extracted from roots or leaves, that can be used in medicine.
The enzyme uses the cofactor, reduced nicotinamide adenine dinucleotide phosphate (NADPH). This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3-oxo-5alpha-steroid:NADP+ Delta4-oxidoreductase. Other names in common use include testosterone Delta4-5alpha-reductase, steroid 5alpha-reductase, 3-oxosteroid Delta4-dehydrogenase, 5alpha-reductase, steroid 5alpha-hydrogenase, 3-oxosteroid 5alpha-reductase, testosterone Delta4-hydrogenase, 4-ene-3-oxosteroid 5alpha-reductase, reduced nicotinamide adenine dinucleotide, phosphate:Delta4-3-ketosteroid 5alpha-oxidoreductase, 4-ene-5alpha-reductase, Delta4-3-ketosteroid 5alpha-oxidoreductase, cholest-4-en-3-one 5alpha-reductase, and testosterone 5alpha-reductase.
=== Evolution === The date of the appearance of smallpox is not settled. It most probably evolved from a terrestrial African rodent virus between 68,000 and 16,000 years ago. The wide range of dates is due to the different records used to calibrate the molecular clock. One clade was the variola major strains (the more clinically severe form of smallpox) which spread from Asia between 400 and 1,600 years ago. A second clade included both alastrim (a phenotypically mild smallpox) described from the American continents and isolates from West Africa which diverged from an ancestral strain between 1,400 and 6,300 years before present. This clade further diverged into two subclades at least 800 years ago. A second estimate has placed the separation of variola virus from Taterapox (an Orthopoxvirus of some African rodents including gerbils) at 3,000 to 4,000 years ago. This is consistent with archaeological and historical evidence regarding the appearance of smallpox as a human disease which suggests a relatively recent origin. If the mutation rate is assumed to be similar to that of the herpesviruses, the divergence date of variola virus from Taterapox has been estimated to be 50,000 years ago. A strain that dates from c. 1650 has been shown to be basal to the other presently sequenced strains.
Sources: en.wikipedia.org
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.
Both act at the same G protein-coupled receptor, but ipamorelin is a short synthetic peptide with modified residues rather than the natural 28-amino-acid hormone. Reports describe weaker effects on appetite and on cortisol or prolactin release than those seen with ghrelin. Its resistance to enzymatic breakdown also differs from that of the natural ligand.
Receptor binding and downstream calcium signaling are well characterized in cell-based systems. Effects measured in whole organisms are less consistent across studies and species. The extent to which selective receptor behavior drives the observed hormonal profile is still debated.
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.